ArticleJournal of thrombosis and thrombolysis2026
A multi-omics approach investigating thrombolysis resistance in acute ischemic stroke thrombi.
Article in Journal of thrombosis and thrombolysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Next-Generation Stroke Biomarkers: Bridging the Gap Between Innovation and Translation.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intravenous thrombolysis outcomes in acute ischemic stroke (AIS) vary widely due to heterogeneous clot responsiveness. Defining the molecular basis of thrombolysis resistance is critical to improving treatment efficacy. Sixty-one clots from 59 AIS patients underwent ex vivo thrombolysis with rtPA and were classified as resistant, undefined, or susceptible based on 1-h lysis rates. Quantitative proteomics was performed on a subset (n = 6/group) using mass spectrometry. Whole-genome sequencing (n = 13) explored genetic associations. Clot composition was assessed using Martius Scarlet Blue staining (n = 11) and correlated with thrombolysis. At 1 h, 37 clots were resistant (0- < 25% lysis), 11 undefined (25- < 40%), and 13 susceptible (40-80%). Clot composition did not correlate significantly with thrombolysis. Proteomics identified 124 differentially expressed proteins (≥ 1.5-fold, p < 0.05), including 108 downregulated and 16 upregulated in resistant clots. Downregulated pathways included oxidative phosphorylation, neutrophil extracellular trap signaling, and integrin-mediated adhesion, while granzyme A signaling and mitochondrial dysfunction were enriched. WGS revealed no group-specific variants. Thrombolysis resistance in AIS clots is not explained by histologic composition alone but is associated with coordinated proteomic alterations in mitochondrial bioenergetics, cytoskeletal organization, and adhesion pathways, identifying mitochondrial bioenergetic failure and integrin-mediated structural remodeling as key determinants of fibrinolysis resistance and potential therapeutic targets.
Indexed as
Identifiers
42449085What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.